Amoxicillin clavulanate 312mg/5ml oral suspension combines 250mg amoxicillin with 62.5mg clavulanic acid per 5ml dose. This pediatric-friendly formulation provides broad-spectrum antibiotic coverage in a palatable liquid form. The 100ml bottle delivers precise dosing for children based on weight and infection severity. After reconstitution, the suspension maintains stability for 7-10 days refrigerated. The 4:1 amoxicillin-to-clavulanate ratio effectively treats resistant ear, nose, throat, and urinary tract infections while minimizing gastrointestinal side effects common in children.
The 312mg/5ml suspension is dosed at 20-40mg amoxicillin/kg/day divided every 12 hours. For otitis media, the higher dose range (40mg/kg/day) is recommended. Use the provided measuring device for accuracy - household spoons vary dangerously. Shake vigorously before each use to ensure proper drug distribution. Administer at the start of meals to enhance absorption and reduce stomach upset. The banana-flavored formulation improves compliance in young children. Treatment typically lasts 7-10 days, with full completion essential even after symptoms resolve to prevent resistance development.
This suspension is first-line for acute bacterial otitis media (82% clinical cure rate), sinusitis, and streptococcal pharyngitis when resistance is suspected. It effectively treats urinary tract infections caused by susceptible E. coli strains. The clavulanate component extends coverage to beta-lactamase producing H. influenzae and M. catarrhalis - common pediatric pathogens. Compared to plain amoxicillin, this formulation reduces treatment failure rates from 25% to 8% in resistant infections. Recent guidelines recommend it for complicated skin infections and human/animal bites when anaerobes are involved.
Reconstitute the dry powder by adding 90ml purified water in two portions, shaking after each addition. The prepared suspension lasts 7 days refrigerated (2-8°C) or 10 days if using the newer stabilized formulations. Never freeze. Write the expiration date on the bottle after mixing. Discard any unused portion after this period as potency decreases. For travel, use insulated containers with ice packs. Always inspect for clumping or unusual odor before administration. Proper preparation ensures accurate dosing and maintains antibiotic efficacy throughout treatment.
Common pediatric reactions include diarrhea (15-20%), diaper rash (10%), and vomiting (5%). The clavulanate component increases diarrhea risk compared to amoxicillin alone. Severe but rare effects include allergic reactions (1-3%) and pseudomembranous colitis (0.1%). Monitor for watery stools, persistent vomiting, or unusual drowsiness. Probiotic supplementation may reduce gastrointestinal effects. Contraindications include penicillin allergy and previous cholestatic jaundice with amoxicillin-clavulanate. Immediate discontinuation is required for severe skin reactions or difficulty breathing.
Premature infants and neonates <3 months require dosage adjustments and closer monitoring. Children with renal impairment need extended dosing intervals (CrCl <30ml/min: 15mg/kg every 24 hours). Those with phenylketonuria should use alternative formulations as the suspension contains aspartame. Diabetic patients must account for the 0.06g sucrose per ml. Overweight children should be dosed by ideal body weight to avoid clavulanate overdose. Parents should receive clear written instructions to prevent dosing errors common in pediatric antibiotic administration.
The 312mg/5ml suspension offers distinct advantages over tablets for pediatric use. It allows precise weight-based dosing unavailable with fixed-dose tablets. The liquid form is essential for children <6 years who cannot swallow pills. Bioavailability studies show suspension achieves 10-15% higher amoxicillin levels than crushed tablets. However, the suspension requires refrigeration and has shorter stability than tablets. Taste acceptance is generally good, though some children prefer the chewable tablet form. Cost comparisons show similar pricing, but suspension avoids the need for pill-splitting or compounding.
Current susceptibility rates for the 4:1 formulation vary regionally: 85-90% of S. pneumoniae, 75% of H. influenzae, and 60% of E. coli remain sensitive in most areas. The clavulanate component restores activity against 90% of beta-lactamase producing M. catarrhalis. Emerging resistance involves altered PBPs in pneumococci and ESBL production in Gram-negatives. Mid-treatment cultures are recommended for persistent symptoms. Antimicrobial stewardship programs emphasize using this formulation only when resistance is likely to preserve its effectiveness against key pediatric pathogens.
The 100ml 312mg/5ml suspension costs $15-$40 depending on manufacturer and pharmacy. Most insurance plans cover it under preferred pediatric formularies without prior authorization. Medicaid programs typically include this strength with minimal copay. The WHO Essential Medicines List includes pediatric amoxicillin-clavulanate, though availability varies in resource-limited settings. Pharmacoeconomic analyses favor this formulation over broader-spectrum alternatives for appropriate indications due to lower resistance selection pressure and cost.
Counsel parents to: use only the provided measuring device, complete the full course, administer with food, and recognize allergic reactions. Demonstrate proper shaking technique and storage requirements. Advise on managing common side effects - continue feeding through diarrhea, use barrier creams for diaper rash. Provide written dosing schedules and emphasize timing consistency. Warn against sharing leftover medication. These instructions reduce errors and improve treatment outcomes in pediatric patients.
Current studies investigate: extended stability formulations (14-day refrigerated life), taste-masked versions to improve compliance, and higher-concentration suspensions (600mg/5ml) to reduce volume burdens. Research continues on optimal dosing for obese children and those with cystic fibrosis. Genetic testing may soon identify patients prone to adverse reactions. New powder formulations allow preparation with any clean water in emergency settings. These innovations aim to maintain this essential pediatric antibiotic's effectiveness and accessibility.
The suspension may reduce oral contraceptive efficacy - advise backup methods in adolescents. Probiotics should be spaced 2-3 hours apart to prevent binding. Concurrent macrolide use may decrease amoxicillin effectiveness. Live bacterial vaccines (oral typhoid, rotavirus) should be delayed until after treatment. Dairy products don't significantly affect absorption when taken with food. These considerations help optimize therapeutic outcomes while minimizing complications in pediatric patients.
This 100ml oral suspension (amoxicillin 250mg + clavulanate 62mg per 5ml) is used for: acute otitis media, sinusitis, pneumonia, and skin infections in children. The liquid formulation allows precise weight-based dosing for patients who cannot swallow tablets.
• Standard dose: 20-40mg amoxicillin/kg/day divided every 8-12 hours
• Use provided measuring syringe - never household spoons
• Shake bottle vigorously for 30 seconds before each use
• Give at start of meals to reduce stomach upset
• Store reconstituted suspension refrigerated (2-8°C) for 7 days only
The 4:1 ratio (250mg amoxicillin + 62mg clavulanate per 5ml) provides optimal clavulanate concentration to overcome bacterial resistance while minimizing diarrhea risk in children. This intermediate strength balances efficacy and tolerability.
While effective against Streptococcus pyogenes, amoxicillin alone is preferred for strep throat unless there's concern for beta-lactamase producing co-infections. The clavulanate component adds unnecessary side effects for simple streptococcal pharyngitis.
Rinse with cool water after each use. Avoid hot water (can damage markings) and soap (may leave residues). Air-dry completely before reassembling. Replace syringe if markings become illegible.
1. Add 64ml water in two portions - shake well after each addition
2. Final volume will be ~100ml (contains extra to account for spillage)
3. Never use hot water - destroys the antibiotic
4. Write preparation date on bottle
5. Discard unused portion after 7 days
• Diarrhea (15-20% of cases - usually mild)
• Diaper rash (10%)
• Vomiting (5%)
• Oral thrush (3%)
• Temporary taste disturbances
These typically resolve within 3 days of completing treatment.
Administer as soon as remembered unless within 2 hours of next dose. For twice-daily dosing, maintain at least 8 hours between doses; for thrice-daily, at least 4 hours. Never give double doses.
May temporarily reduce efficacy of live bacterial vaccines (like rotavirus). Delay these vaccines until 3 days after completing antibiotics. Inactivated vaccines (DTaP, IPV) can be given normally.
Normal settling occurs - just shake vigorously. True clumping (that doesn't dissolve after shaking) indicates improper storage or contamination. Discard if persistent clumps remain after thorough shaking.